ArticleThe oncologist2022

Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.

Yutaka Fujiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.